Sabate, J M <br/><br/>
An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.  [electronic resource] 

 -  Alimentary pharmacology & therapeutics  Jun 2002 
 - 1117-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0269-2813 
<br/><br/><label>Standard No.: </label>10.1046/j.1365-2036.2002.01273.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Chronic Disease<br/>Crohn Disease--complications<br/>Drug Resistance<br/>Female<br/>Fistula--drug therapy<br/>Gastrointestinal Agents--administration & dosage<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Infliximab<br/>Male<br/>Severity of Illness Index<br/>Thalidomide--administration & dosage<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors